SCHEMBL32677481

SCHEMBL32677481

CC(C)(C)OC(=O)NC1CCC(c2ccc(C(=O)OC(C)(C)C)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.51
MAOB P27338 1/20 0.51
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
JAK3 P52333 1/20 0.46
NAMPT P43490 1/20 0.45
DRD2 P14416 4/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
EPHX2 P34913 1/20 0.42
BTK Q06187 1/20 0.42
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.41
NPC1L1 Q9UHC9 1/20 0.40
KCNA3 P22001 1/20 0.40
DRD3 P35462 1/20 0.40
LIPG Q9Y5X9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32677539 0.93 KDM1A (0.50) KDM1AMAOBJAK2JAK1TYK2
SCHEMBL20437077 0.87 CA12 (0.47) NAMPT
SCHEMBL7284536 0.86 KDM1A (0.53) KDM1AMAOBJAK2JAK1TYK2
SCHEMBL7273631 0.86 KDM1A (0.53) KDM1AMAOBJAK2JAK1TYK2
SCHEMBL21232465 0.86 KDM1A (0.48) KDM1AMAOBNAMPTDRD2NFKB1
SCHEMBL21221554 0.86 KDM1A (0.48) KDM1AMAOBNAMPTDRD2NFKB1
SCHEMBL22440099 0.85 KDM1A (0.52) KDM1AMAOBJAK2JAK1TYK2
SCHEMBL29594695 0.85 KDM1A (0.52) KDM1AMAOBJAK2JAK1TYK2
SCHEMBL1570294 0.85 KDM1A (0.52) KDM1AMAOBJAK2JAK1TYK2
SCHEMBL29594710 0.85 KDM1A (0.52) KDM1AMAOBJAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055057-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF PFIZER INC. (US) 2026-02-26 US disclosed
WO-2026042018-A1 4-{4-[(1-{[4-(PROPAN-2-YL)PHENYL]CARBAMOYL)-D-PROLYL)AMINO]CYCLOHEXYL}BENZOIC ACID DERIVATIVES AS GIPR ANTAGONISTS FOR THE TREATMENT OF DIABETES PFIZER INC. (US) 2026-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260055057-A1 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR ANTAGONISTS AND USES THEREOF GIPR, GLP1R, GPR119 KDM1A 3773/4885MAOB 3779/4885JAK2 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.